Osteoporosis is underrecognized and undertreated despite the availability of effective therapies that reduce fracture risks. Bisphosphonates are currently the most widely prescribed pharmacologic ...

In an update to its guidance on primary osteoporosis, ACP recommended bisphosphonates as a first line of defense to reduce fracture risk in men and postmenopausal women. The new guideline, published ...

Osteoporosis has long been recognized as a disease affecting postmenopausal women but it has become increasingly clear that men are affected by low bone density and suffer the consequences of ...

A systematic review and meta-analysis has found that bisphosphonates—medicines commonly used to treat osteoporosis—may offer ...

Peter L. Salgo, MD: Now, something you said rang a bell, because Tom mentioned something, too. You said it’s a chronic disease and you’re never going to get cured, and yet there’s a time limit on ...

Philadelphia, PA - A review of jaw osteonecrosis as a recently described adverse effect of bisphosphonate therapy in the May 16, 2006 issue of the Annals of Internal Medicine concludes that most cases ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window About a year was ...

Researchers found a small but greater risk of a hip fracture after 2 years of taking a "drug holiday" — stopping therapy — after long-term (≥ 3-year) use of one bisphosphonate, risedronate, versus ...

Q: What are your thoughts on prescribing oral bisphosphonates for osteoporosis? I am wary of prescribing them in younger patients because these agents have long half-lives and seem to be associated ...

Please provide your email address to receive an email when new articles are posted on . Despite potential side effects, bisphosphonate therapy may benefit postmenopausal women with osteoporosis by ...